In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson ClinicalTrials.gov number, NCT05083169.).
Costa et al. (Tue,) studied this question.